CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aclaris Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aclaris Therapeutics Inc
640 Lee Rd Ste 200
Phone: (484) 324-7933p:484 324-7933 WAYNE, PA  19087-5636  United States Ticker: ACRSACRS

Business Summary
Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a physician-led, biopharmaceutical company focused on immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. Its drug candidates are ATI-450, ATI-1777, ATI-2138, JAK1/JAK3 Inhibitor, A-101, ATI-501 and ATI-502. Its ATI-450, an investigational oral. small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. Its indirect, wholly owned subsidiary is Confluence Discovery Technologies, Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202012/31/2019YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Co-Founder, Director NealWalker 50 7/1/2012 7/1/2012
Co-Founder, Chief Financial Officer FrankRuffo 54 12/31/2016 7/1/2012
Co-Founder, Chief Compliance Officer, Secretary, Chief Legal Officer KamilAli-Jackson 61 12/31/2016 7/1/2012
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Confluence Life Sciences, Inc. 4320 Forest Park Avenue St. Louis MO United States

Business Names
Business Name
Aclaris Life Sciences, Inc.
Aclaris Therapeutics International Limited
ACRS
Confluence Discovery Technologies, Inc.

General Information
Number of Employees: 77 (As of 12/31/2019)
Outstanding Shares: 41,866,345 (As of 5/6/2020)
Shareholders: 60
Stock Exchange: NASD
Federal Tax Id: 460571712
Fax Number: (302) 655-5049
Email Address: info@vicepttx.com


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, June 06, 2020